Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,217 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07415031RecruitingPhase 2
Long term treatment with adagrasib for solid tumor patients
This trial allows people with solid tumors who are already benefiting from the study drug adagrasib in an earlier Mirati study to continue getting it for the long term. It’s for people whose doctors see ongoing benefit and who still meet the safety rules.
Phoenix, ArizonaAges 18 years+ - NCT07620574Enrolling by invitationPhase 3
Long-Term Study Continuing Cancer Treatment from Previous Trial
This study lets people who were in an earlier Exelixis cancer treatment trial continue receiving the same treatment if it's still helping them. It's designed to see how safe and effective the treatment is over a longer period.
Bay Shore, New YorkAges Any age - NCT07291076RecruitingPhase 1/Phase 2
Study of Pumitamig with Ipilimumab for first-line advanced liver cancer
This trial tests a new drug called pumitamig, either alone or with another drug (ipilimumab), for people with advanced liver cancer that hasn't been treated yet. The goal is to see if these drugs can help shrink or control the cancer.
Duarte, CaliforniaAges 18 years+ - NCT07223658RecruitingPhase 1/Phase 2
Study of ARO-DIMERPA for high triglycerides and cholesterol
This trial tests an experimental drug, ARO-DIMERPA, for people with very high triglycerides and cholesterol. It aims to lower those levels and reduce heart risks.
Charlestown, New South WalesAges 18 years+ - NCT06966024RecruitingPhase 1
Study of DCC-2812 for advanced genitourinary cancers
This trial tests an experimental pill called DCC-2812 for people with advanced kidney, bladder, or prostate cancer. The goal is to see if it is safe and if it might help shrink tumors or slow the cancer's growth.
Boston, MassachusettsAges 18 years+ - NCT03486873RecruitingPhase 3
Study extension for people on pembrolizumab, testing long-term safety
This trial follows people with advanced tumors who are already on pembrolizumab (or similar treatment) to check long-term safety and effectiveness. It may help your care team by monitoring benefits and side effects over a longer period.
Tucson, ArizonaAges 18 years+ - NCT07197788Enrolling by invitation
Continued access to the Endogenex device study for type 2 diabetes
This trial offers continued access to the Endogenex system for people who were in the sham (placebo) group of the ReCET study and have completed their 12-month visit. It tests a device that treats the duodenum to improve blood sugar control.
Miami, FloridaAges 22 years+ - NCT07182149RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new drug called NRM-823 for people with several types of advanced cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
Denver, ColoradoAges 18 years+ - NCT07013487RecruitingPhase 3
Dengue vaccine study for healthy children ages 2 to 17
This trial tests an experimental dengue vaccine in healthy children and teens to see if it can prevent dengue. It may help protect your child from this mosquito-borne illness.
East Jakarta, Jakarta Special Capital RegionAges 2–17 - NCT07463183RecruitingPhase 2
Study of MK-8690 for moderate to severe ulcerative colitis
This trial tests an investigational drug called MK-8690 for people with moderate to severe ulcerative colitis (UC) who haven't responded well to other treatments or can't tolerate them. The study aims to see if the drug can help control UC symptoms safely.
Anaheim, CaliforniaAges 18–75 - NCT07069712RecruitingPhase 2
New drug combinations before and after surgery for stomach or esophageal cancer
This study tests new drug combinations given before and after surgery for people with stomach or gastroesophageal cancer that can be removed but is locally advanced (has grown into nearby tissue). The goal is to see if these combinations can shrink the tumor and improve outcomes.
Newark, DelawareAges 18 years+ - NCT07332091RecruitingPhase 2
Study of vamifeport for adults with iron overload from hereditary hemochromatosis
This study tests an investigational drug called vamifeport to see if it can reduce iron levels in the body and improve outcomes for people with hereditary hemochromatosis (a genetic condition causing too much iron absorption). Participation may help manage iron overload and potentially reduce the need for regular blood removal treatments.
Gilbert, ArizonaAges 18 years+ - NCT07123779RecruitingPhase 1/Phase 2
Study of HS235 in obese patients with pulmonary hypertension and heart failure
This trial tests an investigational drug called HS235 in people who have both obesity (BMI 30-50) and a specific type of heart failure with preserved pumping function, along with high blood pressure in the lungs. The goal is to see if the drug can improve symptoms and quality of life.
Greenville, South CarolinaAges 18 years+ - NCT07222800RecruitingPhase 3
Testing a new drug plus chemo for stage 4 colorectal cancer
This study tests a new experimental drug (PF-08634404) combined with standard chemotherapy for people with stage 4 colorectal cancer who have not yet been treated for their advanced disease. The goal is to see if the combination helps shrink or slow the growth of tumors.
Chandler, ArizonaAges 18 years+ - NCT04728893RecruitingPhase 2
Nemtabrutinib for blood cancers after prior treatment
This Phase 2 trial tests nemtabrutinib (MK-1026), an oral medicine, in people with certain blood cancers that have come back or didn’t respond to earlier treatments. It aims to see how well the drug works and whether it is safe.
Springdale, ArkansasAges 18 years+ - NCT07725939RecruitingPhase 2
Study of Galvokimig for moderate-to-severe COPD with chronic bronchitis
This study tests an experimental drug called Galvokimig (taken as a pill) to see if it can reduce COPD flare-ups and improve lung function in people with moderate to severe COPD and chronic bronchitis. It is for those who have had recent flare-ups and are already using maintenance inhalers.
Columbus, OhioAges 40–80 - NCT07601425RecruitingPhase 1/Phase 2
ATV-1601 Treatment for Hereditary Hemorrhagic Telangiectasia
This trial tests a new drug called ATV-1601 in people with HHT, a genetic condition that causes abnormal bleeding and blood vessel problems. The drug aims to reduce bleeding and anemia caused by HHT.
Boston, MassachusettsAges 18 years+ - NCT07218146RecruitingPhase 3
Study of ZL-1310 vs Standard Care for Relapsed Small Cell Lung Cancer
This trial tests a new drug, ZL-1310, against standard treatments for people with small cell lung cancer that has returned after initial therapy. The goal is to see if ZL-1310 works better than other options.
La Jolla, CaliforniaAges 18 years+ - NCT07226999RecruitingPhase 2/Phase 3
A new study for people with extensive-stage small cell lung cancer using a study drug plus chemo
This trial tests a new study medicine, PF-08634404, combined with chemotherapy for people with extensive-stage small cell lung cancer. It aims to see if this combination works better than standard treatments.
Fayetteville, ArkansasAges 18 years+ - NCT07354724RecruitingPhase 1
Study of DNL952 for adults with late-onset Pompe disease
This trial tests a new drug, DNL952, in adults with late-onset Pompe disease. It aims to see if the drug is safe and how it works in the body, with different groups for people currently on enzyme replacement therapy or those who haven't had it in the past year.
Irvine, CaliforniaAges 18–75 - NCT06842498RecruitingPhase 2
FG-3246 for advanced prostate cancer
This trial tests a new drug called FG-3246, which targets a protein (CD46) on prostate cancer cells. It's for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy, and who have had limited prior treatments.
Goodyear, ArizonaAges 18 years+ - NCT07161700Enrolling by invitationPhase 2
Long-term safety study of SPT-300 for major depression
This study is for people who finished the earlier BUOY-1 study of SPT-300 and want to continue treatment. It tests the long-term safety and tolerability of SPT-300 for major depressive disorder, with or without anxious distress.
Chino, CaliforniaAges 18–66 - NCT07570862RecruitingPhase 2
CAR T-Cell Therapy for Hard-to-Treat Lupus Kidney Disease
This trial tests FT819, a new type of immune cell therapy (CAR T cells), for people with lupus nephritis—kidney inflammation caused by lupus—who haven't responded well to standard treatments. The goal is to see if this therapy can reduce kidney damage and improve kidney function.
Beverly Hills, CaliforniaAges 12–70 - NCT06605378Recruiting
Antibody and cytokine study for people with CGD
This study is checking levels of antibodies and immune-signaling molecules (cytokines) in people with chronic granulomatous disease (CGD). It aims to better understand the immune system in CGD, which may help with future treatments.
Montgomery, AlabamaAges Any age
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,217 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.